Pathological complete response (pCR) rates were highest in HER2-positive (60.2%) and triple-negative (53.1%) breast cancer subtypes and lowest in those who were identified as oestrogen receptor-positive (ER-positive)/HER2-negative (11.1%). The gene discussed is ERBB2; the disease is breast cancer.